XML 133 R51.htm IDEA: XBRL DOCUMENT
v3.22.4

Collaborative and Other Relationships (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Co-promotion profit sharing formula | As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below:
After LUNSUMIO Approval until the First Threshold Date | 37.5 | %
After First Threshold Date until the Second Threshold Date | 35.0 | %
After Second Threshold Date | 30.0 | %
Pretax profit sharing formula | Our share of annual co-promotion profits in excess of $50.0 million varies upon the following events, as summarized in the table below:
Until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
Revenues from anti-CD20 therapeutic programs | Revenue from anti-CD20 therapeutic programs is summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Royalty revenue on sales of OCREVUS |  | $ | 1,136.3 |  |  | $ | 991.7 |  |  | $ | 845.4 |
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA |  | 547.0 |  |  | 647.7 |  |  | 1,080.2 |
Other revenue from anti-CD20 therapeutic programs |  | 17.2 |  |  | 19.1 |  |  | 52.2 |
Total revenue from anti-CD20 therapeutic programs |  | $ | 1,700.5 |  |  | $ | 1,658.5 |  |  | $ | 1,977.8 |
Revenue from anti-CD20 therapeutic programs is summarized as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Royalty revenue on sales of OCREVUS |  | $ | 1,136.3 |  |  | $ | 991.7 |  |  | $ | 845.4 |
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA |  | 547.0 |  |  | 647.7 |  |  | 1,080.2 |
Other revenue from anti-CD20 therapeutic programs |  | 17.2 |  |  | 19.1 |  |  | 52.2 |
Total revenue from anti-CD20 therapeutic programs |  | $ | 1,700.5 |  |  | $ | 1,658.5 |  |  | $ | 1,977.8 |
Summary of activity related to BAN2401 and Elenbecestat collaboration | A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Total development expense incurred by the collaboration related to the advancement of LEQEMBI |  | $ | 347.2 |  |  | $ | 323.0 |  |  | $ | 219.3 |
Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our consolidated statements of income |  | 173.6 |  |  | 161.5 |  |  | 109.6 |
Total sales and marketing expense incurred by the LEQEMBI Collaboration |  | 104.6 |  |  | 27.2 |  |  | 9.8 |
Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income |  | 52.3 |  |  | 13.6 |  |  | 4.9 |
Summary of activity related to Aducanumab collaboration | A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Total ADUHELM development expense |  | $ | 149.4 |  |  | $ | 183.7 |  |  | $ | 152.0 |
Biogen's share of the ADUHELM Collaboration development expense reflected in research and development expense in our consolidated statements of income |  | 82.2 |  |  | 101.1 |  |  | 83.6 |
Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement |  | 134.2 |  |  | 562.3 |  |  | 353.0 |
Biogen's share of the ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our consolidated statements of income |  | 71.5 |  |  | 301.4 |  |  | 193.7 |
Total ADUHELM Collaboration third party milestones |  | — |  |  | 100.0 |  |  | 75.0 |
Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our consolidated statements of income |  | — |  |  | 45.0 |  |  | 33.8 |
Summary of activity related to the UCB collaboration | A summary of development expense related to the UCB collaboration agreement is as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Total UCB collaboration development expense |  | $ | 68.0 |  |  | $ | 84.2 |  |  | $ | 58.3 |
Biogen's share of the UCB collaboration development expense reflected in research and development expense in our consolidated statements of income |  | 34.0 |  |  | 42.1 |  |  | 29.2 |
Summary of Activity Related to Sage Therapeutics | A summary of development and sales and marketing expense related to this collaboration is as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Total Sage collaboration development expense |  | $ | 173.3 |  |  | $ | 167.7 |  |  | $ | — |
Biogen's share of the Sage collaboration development expense reflected in research and development expense in our consolidated statements of income |  | 86.7 |  |  | 83.8 |  |  | — |
Total Sage sales and marketing expense incurred by the collaboration |  | 109.9 |  |  | 36.4 |  |  | — |
Biogen's share of the Sage collaboration sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income |  | 55.0 |  |  | 18.2 |  |  | — |
Summary of Activity Related to Denali Therapeutics Collaboration | A summary of development expense related to this collaboration is as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Total Denali collaboration development expense |  | $ | 75.1 |  |  | $ | 42.5 |  |  | $ | 14.6 |
Biogen's share of the Denali collaboration development expense reflected in research and development expense in our consolidated statements of income |  | 43.8 |  |  | 25.5 |  |  | 8.8 |
Summary of Activity Related to Sangamo Therapeutics | A summary of development expense related to this collaboration is as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2022 |  | 2021 |  | 2020
Total Sangamo collaboration development expense |  | $ | 19.1 |  |  | $ | 22.7 |  |  | $ | 10.1 |
Biogen's share of the Sangamo collaboration development expense reflected in research and development expense in our consolidated statements of income |  | 12.1 |  |  | 14.6 |  |  | 6.4 |

X
- Definition Co-promotion profit sharing formula. + References No definition available. + Details
Name: | biib_CoPromotionProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pretax Profit Sharing Formula [Table Text Block] + References No definition available. + Details
Name: | biib_PretaxProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block] + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to Denali Therapeutics Collaboration + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to Sage Therapeutics + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to Sangamo Therapeutics + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToSangamoTherapeuticsTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to the UCB Collaboration + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration